Corporate ActionMay 19, 2026, 04:07 PM
Galera Therapeutics Converts All Series B Preferred Stock to Common
AI Summary
Galera Therapeutics, Inc. completed the mandatory conversion of all its remaining Series B Non-Voting Convertible Preferred Stock into common stock. A total of 42,839.11 shares of Series B Preferred Stock were converted into 42,839,103 shares of common stock. The company will pay cash in lieu of any fractional shares, and no Series B Preferred Stock remains issued and outstanding after this conversion.
Key Highlights
- Galera Therapeutics converted all remaining Series B Preferred Stock.
- 42,839.11 shares of Series B Preferred Stock were converted.
- 42,839,103 shares of Common Stock were issued upon conversion.
- No fractional shares of Common Stock were issued; cash paid instead.
- Following the conversion, no Series B Preferred Stock remains outstanding.
Price Impact
More from GRTX